Your partner for Dx compliance in translational research


ARC Regulatory announces the appointment of Dr David Ribeiro as Chief Operating Officer

- by Seamus Kearney

Belfast, UK – 11 March 2024 – ARC Regulatory is pleased to confirm the appointment of Dr David Ribeiro to the newly created role of Chief Operating Officer.

ARC,  established in 2010, delivers integrated solutions to the Precision Medicine sector, supporting the implementation and compliant research of in vitro diagnostics (IVD) in precision medicine trials worldwide.  The company’s mission is to be the preferred partner for the global precision medicine and IVD industry, supporting the development of kinder treatments and expediting the highest quality clinical research for improved patient outcomes.

Dr Ribeiro joins the company to provide ongoing oversight, delivery and improvement of company operations and customer success. He will pursue operational excellence during its next stage of high-growth.  David has extensive experience in the health and life sciences sector, having previously held senior leadership roles at Solvay Healthcare, Encysive Pharmaceuticals, Pharmaxis and Pfizer.  Since 2015, David held the role of Chief Executive Officer at ProAxsis Limited, a Belfast-based medical company, focused on the successful development, registration and commercialisation of a range of IVDs for monitoring patients with chronic respiratory diseases.

Seamus Kearney, Founder and CEO of ARC, commented: "I am delighted to welcome David to the expanded senior leadership team as we continue our mission to deliver kinder patient treatments. We are pleased to add David’s extensive experience in the IVD industry to our existing leadership team.”

David Ribeiro added: "ARC is at a hugely exciting time in its evolution as a premier provider of high quality regulatory and clinical research solutions to the precision medicine sector.  ARC’s strength in its people will ensure that the company continues to expand its role in supporting real advances in precision medicine, accelerating time to clinic and delivering study compliance globally and I’m greatly looking forward to joining them on the journey.”

To learn more about opportunities to join ARC’s team, contact [email protected]

Seamus Kearney
Article written by Seamus Kearney
March 12, 2024

Get in touch with our expert team today